Journal
JOURNAL OF PHARMACOLOGICAL SCIENCES
Volume 149, Issue 3, Pages 108-114Publisher
JAPANESE PHARMACOLOGICAL SOC
DOI: 10.1016/j.jphs.2022.04.007
Keywords
Eco-pharma; Cardiomyocyte; Transient receptor potential channel; NADPH oxidase; Protein-protein interaction
Categories
Funding
- Smoking Research Foundation
Ask authors/readers for more resources
This article discusses the global research efforts and outcomes of drug repurposing for the treatment of COVID-19, and introduces a new protein-protein interaction that is common to COVID-19 aggravation and heart failure.
Coronavirus disease 2019 (COVID-19) remains prevalent worldwide since its onset was confirmed in Wuhan, China in 2019. Vaccines against the causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have shown a preventive effect against the onset and severity of COVID-19, and social and economic activities are gradually recovering. However, the presence of vaccine-resistant variants has been reported, and the development of therapeutic agents for patients with severe COVID-19 and related sequelae remains urgent. Drug repurposing, also called drug repositioning or ecopharma, is the strategy of using previously approved and safe drugs for a therapeutic indication that is different from their original indication. The risk of severe COVID-19 and mortality increases with advancing age, cardiovascular disease, hypertension, diabetes, and cancer. We have reported three protein-protein interactions that are related to heart failure, and recently identified that one mechanism increases the risk of SARS-CoV-2 infection in mammalian cells. This review outlines the global efforts and outcomes of drug repurposing research for the treatment of severe COVID-19. It also discusses our recent finding of a new protein-protein interaction that is common to COVID-19 aggravation and heart failure. ?? 2022 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/ 4.0/).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available